Penumbra (PEN) FCF Margin Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 38.00 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 30.00 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 943.00 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 96.00 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -2,196.00 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -20.00 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 2,679.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -461.00 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 417.00 |
| 10 | Penumbra | 12.52 Bn | 11.91 Bn | 253.41 Mn | 1,573.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,573.00 |
| Dec 31, 2025 | 2,248.00 |
| Sep 30, 2025 | 3,319.00 |
| Jun 30, 2025 | 2,977.00 |
| Mar 31, 2025 | 1,560.00 |
| Dec 31, 2024 | 3,316.00 |
| Sep 30, 2024 | -86.00 |
| Jun 30, 2024 | 786.00 |
| Mar 31, 2024 | 2,144.00 |
| Dec 31, 2023 | 1,757.00 |
| Sep 30, 2023 | -14.00 |
| Jun 30, 2023 | 3,449.00 |
| Mar 31, 2023 | 1,551.00 |
| Dec 31, 2022 | -430.00 |
| Sep 30, 2022 | -2,365.00 |
| Jun 30, 2022 | -2,222.00 |
| Mar 31, 2022 | -237.00 |
| Dec 31, 2021 | -1,907.00 |
| Sep 30, 2021 | 869.00 |
| Jun 30, 2021 | -130.00 |
| Mar 31, 2021 | -1,979.00 |
| Dec 31, 2020 | 572.00 |
| Sep 30, 2020 | -330.00 |
| Jun 30, 2020 | -2,514.00 |
| Mar 31, 2020 | -1,032.00 |
| Dec 31, 2019 | 975.00 |
| Sep 30, 2019 | 1,114.00 |
| Jun 30, 2019 | 1,444.00 |
| Mar 31, 2019 | 323.00 |
| Dec 31, 2018 | 3,333.00 |
| Sep 30, 2018 | 1,459.00 |
| Jun 30, 2018 | 1,240.00 |
| Mar 31, 2018 | 1,860.00 |
| Dec 31, 2017 | 1,908.00 |